Log In
Print
BCIQ
Print
Print this Print this
 

biglycan (TVN-102)

  Manage Alerts
Collapse Summary General Information
Company Tivorsan Pharmaceuticals Inc.
DescriptionRecombinant human biglycan (rhBGN)
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1.5M

$1.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today